BeOne Medicines Reports Positive Phase 3 HERIZON-GEA Results at ASCO 2026
CHICAGO, Illinois and SAN CARLOS, California — May 27, 2026 BeOne Medicines announced new clinical findings from the Phase...
artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology NSCLC Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
CHICAGO, Illinois and SAN CARLOS, California — May 27, 2026 BeOne Medicines announced new clinical findings from the Phase...
SOUTH SAN FRANCISCO, Calif., May 7, 2026 ALX Oncology announced promising new clinical findings showing that its investigational CD47...
SAN CARLOS, CALIFORNIA, April 29, 2026 BeOne Medicines has announced that the U.S. Food and Drug Administration (FDA) has...
